Design • Synthesis • SAR • Exposure

Cyclic Peptide
Lead Optimization Services

Advance validated hits through focused analog design, integrated synthesis and data-guided optimization.

Build the next series around what your current lead needs: stronger activity, improved selectivity, greater stability or longer exposure.

SFTI-1 experimental NMR coordinates, PDB 1JBL model 1, with head-to-tail closure and Cys3-Cys11 disulfide
SFTI-1 experimental NMR conformer, PDB 1JBL, model 1. Head-to-tail closure and the Cys3–Cys11 disulfide are retained; this is a reference scaffold, not a designed analog series.
Home / Peptide Drug Design & Development / Cyclic Peptide Lead Optimization

A better next series

Identify What Limits Your Current Lead

Lead optimization starts with a cyclic peptide that already has experimental support. CD ComputaBio connects molecular design, analog synthesis, testing and structure–activity relationship analysis to address the properties that limit its next development step.

01

Potency & Function

Refine contact residues, ring geometry and conformational preferences to improve target recognition or the intended biological response.

Map activity-driving positions →
02

Selectivity

Explore substitutions that distinguish the intended target from related proteins, supported by an agreed counter-target panel.

Compare target profiles →
03

Stability & Exposure

Address degradation-sensitive regions and evaluate longer-acting formats when sustained systemic exposure is a program objective.

Explore exposure strategies →
04

Chemical Practicality

Improve solubility, sample handling, ring closure or purification so the series remains practical to synthesize and test.

Connect design with chemistry →

The optimization brief prioritizes the properties that matter for your application and defines which characteristics of the parent peptide should be retained.

Establish a reliable starting point

Build the Plan Around Your Lead and Data

A complete molecular definition and comparable baseline measurements make each subsequent analog more informative. We review the parent peptide, experimental conditions and chemical quality before selecting an initial design matrix.

Binding, functional activity and cellular response are considered separately. Apparent potency differences can reflect assay format, sample concentration or solubility as well as chemical changes. The first campaign therefore includes the parent reference and controls that support interpretation.

The baseline review also identifies missing comparisons that could change interpretation. For example, a linker-bearing analog should be compared with the unmodified parent in the same assay, while a stability-oriented substitution should retain a direct activity measurement.

Projects can begin with a single validated hit or an existing series. When recognition still needs independent confirmation, our cyclic peptide screening and hit validation services provide the appropriate starting stage.

From substitutions to useful relationships

Map SAR Across the Macrocycle

A focused analog panel tests explicit hypotheses. Initial scans identify sensitive positions and tolerated changes; subsequent rounds combine favorable modifications and test whether their effects remain beneficial together.

Design dimensionAnalog strategiesQuestion answered
Contact residuesAlanine scans, conservative replacements and selected side-chain changes.Which positions drive binding or function?
Stereochemistry & side chainsD-residues, noncanonical building blocks and charge or volume adjustments.Can interactions or degradation resistance improve?
Ring size & closure positionResidue additions or deletions and alternative cyclization sites.Does the constraint support an active conformation?
Backbone chemistryPosition-specific N-methylation or suitable backbone replacements.How do backbone changes affect conformation and properties?
Cyclization linkageAppropriate disulfide, thioether or amide-linked variants.Which connectivity balances activity, stability and synthesis?
Attachment positionsLinker, label or half-life-extension attachment scans.Where can the molecule tolerate added functionality?

Scans are chosen around the scaffold: replacing glycine, proline or a cyclization residue can alter ring geometry as well as a local contact. Such variants are interpreted as combined structural changes. Initial panels favor informative comparisons over large collections of unrelated modifications.

Use Structure to Explain the Experiment

Cyclic peptide structure modeling can help interpret binding hypotheses, local flexibility and steric effects. Models guide analog nomination; measured results establish SAR.

Preserve What the Series Teaches

Each compound is linked to its design rationale, full chemical definition and experimental record. Negative results help identify restricted positions and guide the next set of changes.

Make the hypothesis testable

Synthesize Focused Analog Panels

Discovery-stage synthesis translates the design matrix into defined samples. Route selection considers solid-phase assembly, protection strategy, cyclization order, building-block availability and late-stage modifications.

For quantitative comparisons, chromatographic purity is considered alongside counterions, residual solvent and peptide content when these affect stock preparation. Material specifications are matched to the assay and scale, with the same reporting conventions used throughout the series.

Ring-closure behavior and purification results feed back into design. Difficult analogs may prompt alternative closure positions, coupling strategies or residue choices, with changes documented so biological comparisons remain interpretable.

Conceptual analog design, synthesis and QC, biological testing and SAR review workflow
Conceptual design–make–test–learn workflow, including analytical QC and biological testing. No experimental results are depicted.

Build

Prepare agreed analogs, controls, noncanonical residues and selected linkers or lipid modifications.

Qualify

Use HPLC and LC-MS for chromatographic purity and mass assessment, with supplementary characterization for connectivity or isomer questions.

Release for Testing

Record batch identity, quantity, purity, concentration basis, stock preparation and storage conditions.

Synthesis deliverables include the agreed samples and analytical records, together with observations relevant to the next analog set or later process development.

Optimize the complete profile

Balance Activity, Selectivity and Molecular Properties

BIOLOGY

Potency & Function

Compare parent and analogs using appropriate binding, competition and functional assays. Define whether affinity, inhibitory potency, receptor response or another endpoint drives prioritization. Suitable SPR or BLI studies can complement biochemical and cellular readouts.

DISCRIMINATION

Selectivity

Assess related proteins or designated counter-targets under matched conditions. Cross-species requirements are built into the panel. For intracellular objectives, cellular activity and target engagement help connect molecular recognition with exposure in the relevant setting.

DEVELOPABILITY

Stability & Handling

Evaluate plasma, serum or relevant protease stability alongside solubility, aggregation risk and chemical integrity. Where degradation products are characterized, the findings can direct changes to susceptible positions or linkages.

Make comparisons meaningful.

Parent references, suitable concentration ranges, repeats and consistent assay conditions support ranking. A more potent analog with poorer solubility may require another chemistry round. Our peptide developability assessment helps organize additional property questions.

A dedicated exposure module

Engineer Stability and Half-Life Around the Intended Use

Exposure optimization begins by identifying the relevant limitation. Proteolytic degradation, rapid clearance and administration-related behavior call for different experiments. A longer-acting format is selected around the dosing and biological objective.

Human serum albumin C-alpha trace and native palmitate ligands from PDB 1E7H chain A
Human serum albumin Cα trace with crystallographic palmitate ligands, PDB 1E7H, chain A. No peptide-conjugate binding pose is implied.
01 / STABILIZE

Protect the Active Molecule

Explore site-specific residue, backbone or cyclization changes informed by degradation data. Measure intact peptide over time in the relevant matrix and compare activity after modification.

02 / EXTEND

Design Long-Acting Analogs

Evaluate lipidation, albumin-binding motifs and suitable linkers at tolerated attachment positions. Compare solubility, albumin association and retained target activity in relevant albumin conditions.

03 / CONFIRM

Measure the Exposure Profile

Scope appropriate in vivo PK and bioanalysis around species, dose and route. Interpret half-life, clearance and AUC together, including free-versus-total exposure where needed.

Connect Albumin Binding with Biological Performance

Linker length, attachment position and binding-group chemistry can change both albumin association and target access. Species differences and assay conditions are therefore included in planning. Serum stability, albumin affinity and in vivo elimination half-life remain distinct endpoints, each supported by its corresponding experiment. Bioanalytical planning specifies whether the assay measures intact parent, a tagged species or a broader signal, so apparent persistence can be interpreted against the molecular form of interest.

A published chemistry-to-exposure example

Use Experimental Evidence to Guide Long-Acting Design

A published study optimized peptide–fatty acid albumin-binding tags through iterative substitutions and binding measurements, then attached an evolved tag to bioactive bicyclic peptides. The work connects sequence changes, synthesis and downstream characterization within an experimental optimization program.1

Published synthesis scheme and albumin-binding measurements for peptide-fatty acid tags
Peptide–fatty acid tag architecture, solid-phase synthesis and albumin-binding characterization.1

This literature example supports the design logic for testing attachment chemistry and albumin association. The choice of modification, experimental system and success criteria is defined for each lead series.

A repeatable optimization cycle

Design. Make. Test. Learn.

Each round ends with an explicit decision: combine a beneficial change, investigate an inconsistent result, redirect the chemistry or advance a defined series. Candidate count and iteration depth follow the learning objective.

01

Baseline

Review parent structure, material and data.

Output: goals and reference profile.
02

Design

Build the analog and assay matrices.

Output: nominated chemistry set.
03

Make

Synthesize, cyclize and characterize.

Output: qualified test samples.
04

Test

Measure activity and selected properties.

Output: comparable assay results.
05

Learn

Integrate SAR and prioritize changes.

Output: next round or lead series.

Choose the Next Set on More Than One Score

Ranking combines the agreed biological endpoint with selectivity, stability, solubility, chemical quality and synthesis behavior. Closely related analogs are compared directly where informative. Design rationale, assay conditions and unresolved questions remain visible in the final recommendations.

Modular work packages

Choose the Scope That Fits Your Lead Series

A / FOCUSED

SAR Campaign

For a validated hit needing position-level understanding. Combine a focused scan with synthesis and selected assays to identify sensitive residues and modification-tolerant regions.

Primary decision: where to optimize next.

B / INTEGRATED

Lead Optimization

For a series with several linked performance gaps. Coordinate design, synthesis, activity and property testing through agreed review points and experimental iterations.

Primary decision: which series merits advancement.

C / EXPOSURE

Half-Life Optimization

For an active series requiring improved stability or systemic exposure. Compare suitable long-acting modifications and connect their biological profile with staged PK studies.

Primary decision: which modified format to develop.

The proposal defines analog numbers, synthesis quantity and purity, assay panels, iteration rounds and any PK scope before work begins.

Every compound connected to its evidence

Receive a Traceable Optimization Package

✓

Baseline and Campaign Plan

Parent profile, prioritized limitations, design hypotheses and the agreed comparison criteria.

✓

Chemically Defined Analog Matrix

Full structures, stereochemistry, linkage definitions, modification positions and design rationale.

✓

Samples and Analytical Records

Contracted analog materials, batch details, chromatograms, mass data and relevant supplementary characterization.

✓

Activity and Property Results

Agreed binding, functional, selectivity, stability or exposure data with conditions and controls.

✓

SAR and Candidate Ranking

Structure–activity and property comparisons, parent benchmarks and multi-parameter prioritization.

✓

Next-Round Recommendations

Proposed changes, remaining evidence gaps and a practical path to further optimization or follow-up studies.

For programs starting without an established peptide, explore AI-guided de novo design. For an oral development objective, continue into our oral cyclic peptide discovery services for permeability, intestinal stability and oral-exposure planning.

Planning your next round

Frequently Asked Questions

What data are needed to begin?

Share the full chemical structure, existing activity results, assay conditions and the property you want to improve. Available sample and analytical records help establish the baseline.

Can you optimize a lead discovered elsewhere?

Yes. Leads from internal screens, external providers or computational programs can be reviewed. The initial plan reflects how well the current activity and molecular identity are supported.

Can synthesis and biological testing be included?

Yes. The campaign can connect analog design, sample preparation, characterization and agreed assays. Each round is organized around an explicit comparison and decision.

Can residues and cyclization chemistry be changed?

Noncanonical residues, stereochemistry and closure strategies can be evaluated against the parent scaffold, available chemistry and the biological hypothesis.

How are analogs selected for the next round?

We examine SAR, data consistency and the agreed property priorities, then nominate changes that test the most useful remaining hypotheses.

Can half-life optimization be included?

Yes. Stability assessment, long-acting analog design and PK confirmation can be staged according to the lead profile, intended route and exposure objective.

Turn your current lead into the next experiment

Bring Your Lead.
Define the Next Optimization Cycle.

Send the complete structure, supporting data, main performance gap and intended application. We will help define a focused design, synthesis and testing plan.

Share structures and supporting files at contact@computabio.com.

Reference

  1. Zorzi, A.; Middendorp, S. J.; Wilbs, J.; Deyle, K.; Heinis, C. Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides. Nature Communications 2017, 8, 16092. doi:10.1038/ncomms16092. Figure 1 reproduced under Creative Commons Attribution 4.0.

Online Inquiry

Submit your project details below, and our team will respond within 24 hours.

x
Need help getting the data you need?

Talk to our technical team about your project!

I Want To Talk